Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Incidence, Natural History and Outcomes of Transient and Persistent Antiphospholipid Antibodies in Children and Young Adults with Provoked Venous Thromboembolism: Analysis of the Kids-DOTT Trial

Marisol Betensky, MDMPH, Anh Thy Nguyen, MSPH, Cristina Tarango, MD, Anupam R Verma, MD, Rukhmi Bhat, MDMS, Nicole Kucine, MD, Charles Nakar, MD, Gary Woods, MD, Frances L Hamblin, MSHS, RN, Ernest Amankwah, PhD, Neil A Goldenberg, MD PhD

Blood (2019) 134 (Supplement_1): 636.

https://doi.org/10.1182/blood-2019-131438

Published: 2019

Journal Articles

Development of a Neural Network to Predict Thrombosis in the Antiphospholipid Syndrome with an Accuracy of 87%

Romy Kremers, PhD, Stéphane Zuily, MD PhD, Philip De Groot, PhD, Coenraad Hemker, MD PhD, Denis Wahl, MD PhD, Bas De Laat, MD, PhD

Blood (2018) 132 (Supplement 1): 3796.

https://doi.org/10.1182/blood-2018-99-115834

Published: 2018

Journal Articles

Yearly Percent Incidence of Suspected Novel Oral Anticoagulant Interference on Thrombophilia Testing: A Nine Year Experience at a Reference Coagulation Laboratory

Edward C.C. Wong, MD MA, Laura A. Worfolk, PhD, Jeffrey S. Dlott, MD

Blood (2018) 132 (Supplement 1): 4819.

https://doi.org/10.1182/blood-2018-99-112972

Published: 2018

Journal Articles

Centralized Laboratory Testing for Inhibitors in the U.S. Hemophilia Treatment Centers Network: Testing Protocol and Results on 10,178 Specimens

Connie H Miller, PhD, Dorothy Ellingsen, Jennifer Driggers, Brian Boylan, Amanda B. Payne, MPH, Fiona Bethea, MPH, Vanessa R Byams, MPH, J. Michael Soucie, PhD, Christopher J. Bean, PhD

Blood (2017) 130 (Supplement 1): 3692.

https://doi.org/10.1182/blood.V130.Suppl_1.3692.3692

Published: 2017

Journal Articles

Long Term Monitoring of Patients with Positive Lupus Anticoagulant and Antiphospholipid Antibodies. Are All Cases Persistently Positive?

Matthew R. Kovacs, Alejandro Lazo-Langner, MD MSc, FRCPC, Martha L Louzada, MD, Michael J. Kovacs, MD FRCPC

Blood (2016) 128 (22): 1452.

https://doi.org/10.1182/blood.V128.22.1452.1452

Published: 2016

Journal Articles

Dilute Russell Viper Venom Time Interpretation and Clinical Correlation: A Two-Year Retrospective Institutional Review

Cyril Jacquot, MDPhD, Geoffrey D. Wool, MD PhD, Scott C. Kogan, MD

Blood (2016) 128 (22): 2609.

https://doi.org/10.1182/blood.V128.22.2609.2609

Published: 2016

Journal Articles

A Case Series of Antiphospholipid Syndrome Patients

Michael Macklin, PharmD, Donald V Woytowitz, Jr., MD

Blood (2016) 128 (22): 5003.

https://doi.org/10.1182/blood.V128.22.5003.5003

Published: 2016

Journal Articles

Prevalence and Financial Impact of Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting: A Retrospective Analysis

Eric Mou, MD, Henry Kwang, MD, Jason Hom, MD, Lisa Shieh, MD, Neera Ahuja, MD, Stephanie Harman, MD, Tyler Johnson, MD, Andre Kumar, MD, Neil Shah, MD, Ronald Witteles, MD, Caroline Berube, MD FRCP(C)

Blood (2016) 128 (22): 2330.

https://doi.org/10.1182/blood.V128.22.2330.2330

Published: 2016

Journal Articles

Andexanet Alfa Corrects the Interference of Direct Factor Xa Inhibitors on Lupus Anticoagulant Testing

Ross I Baker, MD, Grace Gilmore, Scott McGregor, BPharm

Blood (2016) 128 (22): 2626.

https://doi.org/10.1182/blood.V128.22.2626.2626

Published: 2016

Journal Articles

Non-Warfarin Oral Anticoagulants in Anti-Phospholipid Syndrome

Paul Kunk, MD, B. Gail Macik, MD, Melissa Rice, MD

Blood (2015) 126 (23): 1133.

https://doi.org/10.1182/blood.V126.23.1133.1133

Published: 2015

Journal Articles

Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs

Shermin Sayani, BS, Omer Iqbal, MD, Debra Hoppensteadt, PhD, Jawed Fareed, PhD

Blood (2014) 124 (21): 4267.

https://doi.org/10.1182/blood.V124.21.4267.4267

Published: 2014

Journal Articles

Usefulness of Dilute Russell’s Viper Venom Clotting Time (DRVVT) for the Routine Monitoring of New Oral Anticoagulants

Debra Hoppensteadt, PhD, Jake Kola, Mark Brayne, Omer Iqbal, MD, Jawed Fareed, PhD

Blood (2014) 124 (21): 1537.

https://doi.org/10.1182/blood.V124.21.1537.1537

Published: 2014

Journal Articles

Association of Annexin A5 Resistance with Silent Infarct in Sickle Cell Disease

Kerry A. Morrone, MD, Xue Xiaonan, PhD, Suzette O. Oyeku, MD MPH, Jane A. Little, MD, Catherine Driscoll, MD, Jacob Rand, MD, Deepa Manwani, MD

Blood (2014) 124 (21): 1394.

https://doi.org/10.1182/blood.V124.21.1394.1394

Published: 2014

Journal Articles

Efficacy and Safety of Rivaroxaban: An Observationalmulticenter Cohort Study Reporting the Routine Use in Adolescents & Adults with DVT

Manuela Krause, MD, Alexander Bauer, Hartmut Clausnizer, Gili Kenet, MD, Dorothee Kowalski, Verena Limperger, Ann-Kathrin Pilgrimm-Thorp, Daniela Manner, MD, Ulrike Nowak-Göttl, Prof.

Blood (2014) 124 (21): 5083.

https://doi.org/10.1182/blood.V124.21.5083.5083

Published: 2014

Journal Articles

Circulating Levels of Rivaroxaban Provide Different Results in Different Clot Based and Amidolytic Assays. a Study on Patients Treated with Two Different Dosages of Rivaroxaban

Debra Hoppensteadt, PhD, Daneyal Syed, BS, Mateja Jezovnik, Pavel Poredos, Sermin Tetik, Omer Iqbal, MD, Jeanine M. Walenga, PhD, Jawed Fareed, PhD

Blood (2014) 124 (21): 5084.

https://doi.org/10.1182/blood.V124.21.5084.5084

Published: 2014

Journal Articles

Is Dilute Russell’s Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etexilate?

Jonathan Douxfils, Pharm D, PhD Student, Anne Tamigniau, Pharm D, Bernard Chatelain, Professor, Bérangère Devalet, M.D., Pierre Wallemacq, Professor, Paul Hjemdahl, Professor, Yuko Rönquist-Nii, Jean-Michel Dogné, Professor, François Mullier, PhD

Blood (2013) 122 (21): 3634.

https://doi.org/10.1182/blood.V122.21.3634.3634

Published: 2013

Journal Articles

Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants

Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, PhD, Josephine Cunanan, Omer Iqbal, MD, Jawed Fareed, Ph.D.

Blood (2013) 122 (21): 3642.

https://doi.org/10.1182/blood.V122.21.3642.3642

Published: 2013

Journal Articles

Prognostic Factors for Post-Thrombotic Syndrome in Children with Limb DVT: A Bi-Institutional Cohort Study

Courtney A. Lyle, MD, MAS, Elizabeth Gibson, PA-C, Amy Lovejoy, MD, Neil A Goldenberg, MD, PhD

Blood (2012) 120 (21): 3401.

https://doi.org/10.1182/blood.V120.21.3401.3401

Published: 2012

Journal Articles

Baseline Laboratory Parameters Potentially Associated with Thrombophilia in Patients with Chronic ITP.

Raymond S.M. Wong, Kalpana Bakshi, BS, MS, Andres Brainsky, MD

Blood (2012) 120 (21): 2191.

https://doi.org/10.1182/blood.V120.21.2191.2191

Published: 2012

Journal Articles

Effects of Dabigatran and Rivaroxaban On Routine and Specialized Coagulation Assays: A Study Using Actual Patient Plasma Samples

Tyler W. Smith, MD, FRCPC, Leslie Zypchen, MD, FRCPC, Cedric J. Carter, MD, FRCPC, Annie Tran, Pamela Colley, NP, Kenneth Gin, MD, FRCPC, Philip Teal, MD, FRCPC, Bassam A. Masri, MD, FRCSC, Agnes Y.Y. Lee, MD, MSc, FRCPC

Blood (2012) 120 (21): 23.

https://doi.org/10.1182/blood.V120.21.23.23

Published: 2012

NARROW

Incidence, Natural History and Outcomes of Transient and Persistent Antiphospholipid Antibodies in Children and Young Adults with Provoked Venous Thromboembolism: Analysis of the Kids-DOTT Trial

Development of a Neural Network to Predict Thrombosis in the Antiphospholipid Syndrome with an Accuracy of 87%

Yearly Percent Incidence of Suspected Novel Oral Anticoagulant Interference on Thrombophilia Testing: A Nine Year Experience at a Reference Coagulation Laboratory

Centralized Laboratory Testing for Inhibitors in the U.S. Hemophilia Treatment Centers Network: Testing Protocol and Results on 10,178 Specimens

Long Term Monitoring of Patients with Positive Lupus Anticoagulant and Antiphospholipid Antibodies. Are All Cases Persistently Positive?

Dilute Russell Viper Venom Time Interpretation and Clinical Correlation: A Two-Year Retrospective Institutional Review

A Case Series of Antiphospholipid Syndrome Patients

Prevalence and Financial Impact of Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting: A Retrospective Analysis

Andexanet Alfa Corrects the Interference of Direct Factor Xa Inhibitors on Lupus Anticoagulant Testing

Non-Warfarin Oral Anticoagulants in Anti-Phospholipid Syndrome

Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs

Usefulness of Dilute Russell’s Viper Venom Clotting Time (DRVVT) for the Routine Monitoring of New Oral Anticoagulants

Association of Annexin A5 Resistance with Silent Infarct in Sickle Cell Disease

Efficacy and Safety of Rivaroxaban: An Observationalmulticenter Cohort Study Reporting the Routine Use in Adolescents & Adults with DVT

Circulating Levels of Rivaroxaban Provide Different Results in Different Clot Based and Amidolytic Assays. a Study on Patients Treated with Two Different Dosages of Rivaroxaban

Is Dilute Russell’s Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etexilate?

Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants

Prognostic Factors for Post-Thrombotic Syndrome in Children with Limb DVT: A Bi-Institutional Cohort Study

Baseline Laboratory Parameters Potentially Associated with Thrombophilia in Patients with Chronic ITP.

Effects of Dabigatran and Rivaroxaban On Routine and Specialized Coagulation Assays: A Study Using Actual Patient Plasma Samples

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only